NASDAQ:RPRX

Royalty Pharma Stock News

Healthcare > Biotechnology

Buy RPRX

*Your capital is at risk

$53.57

+0.610 (+1.15%)

At Close: Jun 22, 2026

Royalty Pharma (RPRX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

10:31am, Wednesday, 05'th Nov 2025

Although the revenue and EPS for Royalty Pharma (RPRX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with W

Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates

09:26am, Wednesday, 05'th Nov 2025

Royalty Pharma (RPRX) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.04 per share a year ago.

Royalty Pharma Reports Third Quarter 2025 Results

07:00am, Wednesday, 05'th Nov 2025

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised full year 2025 guidance: Portfolio Receipts expected t

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

07:15am, Tuesday, 04'th Nov 2025

NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by B

How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

12:41pm, Friday, 31'st Oct 2025

Investing in biotechnology often feels like navigating a minefield. A single failed clinical trial can decimate a stock, while a blockbuster approval can generate spectacular returns.

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

11:07am, Wednesday, 29'th Oct 2025

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Royalty Pharma Declares Fourth Quarter 2025 Dividend

08:15am, Friday, 17'th Oct 2025

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordin

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

04:15pm, Thursday, 09'th Oct 2025

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S

Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report?

01:11pm, Wednesday, 08'th Oct 2025

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

09:51am, Monday, 06'th Oct 2025

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

08:15am, Monday, 29'th Sep 2025

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent di

Royalty Pharma plc (RPRX) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

05:23pm, Tuesday, 23'rd Sep 2025

Royalty Pharma plc (NASDAQ:RPRX ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 2:50 PM EDT Company Participants Marshall Urist - Executive Vic

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by